# AMIGO-1 (NCT05299125)

> Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05299125
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Latin American Cooperative Oncology Group
- Conditions: Metastatic Non-small Cell Lung Cancers
- Interventions: Amivantamab; Lazertinib; Pemetrexed 500 mg
- Enrollment: 54
- Primary outcome: To evaluate the 18-month progression-free survival (PFS) rate

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 4
- YouTube: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=amigo-1-nct05299125